As the “engine” of the human circulatory system, the heart normally contracts in a steady rhythm to supply blood and oxygen throughout the body. However, when the myocardium contracts in an excessively forceful and abnormal way, blood supply efficiency does not improve—instead, serious and potentially life-threatening risks may arise. This is the core challenge faced by patients with obstructive hypertrophic cardiomyopathy (oHCM).
In recent years, innovative therapies targeting the mechanism of myocardial contraction have gradually entered public view. Aficamten Tablets are one such example. Approved for global first launch in China, this therapy provides a more mechanism-oriented treatment option for patients with oHCM. Its clearly defined therapeutic positioning and expanding clinical application scenarios are gradually addressing long-standing unmet needs in the management of this condition.
Hong Kong DengYue Medicine has observed that global awareness of “cardiomyopathy-related symptoms” has traditionally been concentrated in Europe and North America. This situation is now changing. More medical innovations originating from China are moving from the laboratory into international clinical practice, expanding treatment options and potentially improving quality of life for patients worldwide.
Understanding the Disease First: Obstructive Hypertrophic Cardiomyopathy Behind “Myocardial Overload”
To understand the therapeutic value of Aficamten, it is first necessary to clarify the condition it targets—obstructive hypertrophic cardiomyopathy (oHCM). This is a common inherited heart disease characterized by abnormal thickening of the myocardium, particularly excessive hypertrophy of the left ventricular wall. As a result, the left ventricular outflow tract becomes narrowed, leading to obstruction of blood flow. In simple terms, the heart muscle becomes “too thick and strong,” blocking the pathway through which blood leaves the heart, thereby triggering a range of symptoms and risks.
Clinical data indicate that hypertrophic cardiomyopathy is one of the most common causes of sudden cardiac death in adolescents and athletes. Among all patients with hypertrophic cardiomyopathy, approximately two-thirds have the obstructive form, which is associated with a poorer prognosis. In these patients, myocardial contractility is excessively hyperactive—“overworking” the heart. This excessive contraction further aggravates outflow tract obstruction, leading to an elevated left ventricular outflow tract pressure gradient (LVOT-G), a key driver of disease progression and cardiac dysfunction. Compared with non-obstructive forms, mortality in oHCM patients is reported to be approximately doubled.
The clinical manifestations of oHCM are often insidious and progressive. Early stages may present with few noticeable symptoms. As the disease progresses, patients may gradually develop exertional dyspnea, chest pain, fatigue, syncope or near-syncope, significantly affecting daily activities and exercise tolerance. More importantly, sudden cardiac death, heart failure, and thromboembolic events represent major long-term risks. Around 43.5% of patients may progress to heart failure with preserved ejection fraction, and approximately 20% develop atrial fibrillation, which is a major risk factor for thromboembolism. These complications place a substantial burden on both physical health and psychological well-being.
Which Conditions Does Aficamten Primarily Target?
Aficamten is a new-generation cardiac myosin inhibitor. Its core therapeutic focus is:
Obstructive hypertrophic cardiomyopathy (oHCM).
This inherited myocardial disorder is typically characterized by:
● Abnormal myocardial hypertrophy
● Obstruction of the left ventricular outflow tract
● Excessively strong but inefficient cardiac contraction
● Shortness of breath, fatigue, chest tightness, palpitations after exertion, with syncope risk
The development goal of Aficamten is to modulate the excessive activity of myocardial contractile proteins, helping the heart contract in a more balanced manner and thereby relieving outflow tract obstruction.
Which Symptoms and Functional Aspects May Be Improved?
Based on clinical research design, the therapeutic goals of Aficamten focus on symptom relief and functional improvement, including:
● Improving exercise tolerance and reducing shortness of breath and fatigue during walking or stair climbing
● Helping alleviate chest tightness and palpitations
● Reducing left ventricular outflow tract pressure gradient
● Improving quality-of-life scores in some patients
It should be emphasized that such therapies are not intended to “cure” the disease, but rather to support long-term symptom control and functional improvement as part of chronic disease management.
How Is It Different From Traditional Cardiac Medications?
Compared with conventional cardiovascular medications, Aficamten differs mainly in its mechanism of action:
Dimension | Traditional Drugs | Aficamten |
Mechanism of Action | Mainly affects heart rate and blood pressure | Directly acts on myocardial contractile proteins |
Target of Action | Biased towards "overall regulation" | More biased towards "etiological mechanism level regulation" |
Indications | Focuses on angina, arrhythmias, etc. | Obstructive hypertrophic cardiomyopathy |
Treatment Goals | Symptom relief | Symptom relief + improvement in hemodynamics |
● Traditional therapies primarily regulate heart rate and blood pressure
● Aficamten directly targets myocardial contractile proteins involved in disease mechanisms
This mechanism-based difference gives Aficamten more specific targeting value in the particular disease subtype of hypertrophic cardiomyopathy with obstruction.
Conclusion
According to the approved indications by China’s National Medical Products Administration and current clinical practice, the use of Aficamten Tablets is clearly defined to ensure appropriate and safe application and to avoid misuse. The core indicated population includes
adult patients with obstructive hypertrophic cardiomyopathy (oHCM) with NYHA class II–III functional status. The main treatment goals are to improve exercise capacity and clinical symptoms, relieve left ventricular outflow tract obstruction, slow disease progression, and reduce the risk of adverse outcomes such as heart failure and sudden cardiac death.
Within the treatment pathway of obstructive hypertrophic cardiomyopathy, Aficamten Tablets represent a therapeutic approach based on myocardial contractility mechanisms. For some patients whose symptoms are not adequately controlled with existing therapies, this type of new-mechanism medicine may become an additional option within a comprehensive management strategy.
Hong Kong DengYue Medicine believes that the ultimate measure of meaningful innovation is simple:Whether it genuinely improves patients’ lives.
No comments:
Post a Comment